MEETING

 Perspectives and Research Advancements in Oncology

 PRATOBreast

 PRATO  |  APRIL 18-19 2024

 COURSE DIRECTORS
 Laura Biganzoli, Luca Malorni

 www.accmed.org  9 CME credits
In recent years, the progress of scientific research in the study of breast tumours has led to the acquisition of multiple novelties in the diagnostic, prognostic and therapeutic fields with profound repercussions on the approach to the patient. Looking ahead, the scenario will be enriched in the near future by further innovations that will certainly represent new opportunities for patients, but also new challenges for the oncology community that will have to manage an increasingly complex subject. This residential event benefits from the participation of a faculty of experts who, thanks to their recognized expertise and experience, will outline the state-of-the-art and future perspectives for the numerous topics covered while animating active discussion with all participants. The aim of the event is twofold: on the one hand, we want to offer an insight into the present by delving into the progress of clinical and translational research in the field of breast cancer; on the other we will try to anticipate future challenges by grasping new perspectives. The discussion will range from the controversial aspects of systemic treatment in early-stage disease, the needs of special populations and the evidence on the newest treatment strategies including antibody-drug conjugates and immune-therapy, to new perspectives in tumour genomics and the treatment of endocrine-resistant tumours.

Medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

With the endorsement of:
13.00  Registro e welcome lunch

14.00  Opening and welcome
Laura Biganzoli, Luisa Fioretto, Cristina Manetti, Maria Teresa Mechi

14.20  A critical review of the past, present and future “revolutions” in systemic therapy for breast cancer
Introduction: Laura Biganzoli
Speaker: Martine Piccart

WHAT’S HOT FOR SYSTEMIC THERAPY OF EARLY BREAST CANCER
Chairs: Rossana Berardi, Pierfranco Conte, Alessandra Fabi

14.50  Keynote 522. Lesson learned and open questions
Lucia Del Mastro

15.10  CDK4/6 inhibitors in the adjuvant treatment of HR+HER2- tumors. Which one and to whom?
Laura Biganzoli

15.30  Are we ready for de-escalation in the treatment of HER2+ breast cancer?
Valentina Guarneri

15.50  Discussion

16.10  Coffee-break

UNMET NEEDS IN SPECIAL POPULATIONS
Moderatori: Francesco Perrone, Ilaria Pazzagli

16.30  Unmet needs in young patients with breast cancer
Angela Toss

16.45  BRCA testing in clinical practice
Luca Livraghi

17.00  Special needs in elderly patients
Emanuela Risi

17.15  Discussion

BREAST CANCER GENOMICS: STATE OF THE ART AND FUTURE APPLICATIONS
Moderatori: Silvia Bessi, Daniele Generali, Giancarlo Pruneri

17.35  Current clinical use of genomic profiling in breast cancer
Mario Giuliano

17.50  Dissecting molecular landscape of metastatic breast cancer: the AURORA-EU initiative
Matteo Benelli

18.05  What's next for circulating biomarkers
Gabriele Zoppoli

18.20  Luminal MBC: let's talk about patient's stratification
Luca Malorni

18.35  Discussion

18.50  Adjourn
09.00  **LECTURE**  
*Predicting response and toxicity in patients with cancer treated with antibody-drug conjugates*  
*Introduction:* Laura Biganzoli  
*Speaker:* Giuseppe Curigliano

**TACKLING ENDOCRINE RESISTANCE IN 2024**  
**Moderatori:** Sabino De Placido, Francesca Martella, Ilenia Migliaccio

09.30  **Current treatment algorithm**  
Grazia Arpino

09.45  **Mechanisms of resistance to CDK4/6 inhibitors**  
Cristina Guarducci

10.00  **Tackling endocrine resistance in the clinic: new endocrine agents and combinations**  
Carmen Criscitiello

10.15  **Discussion**

10.45  *Coffee break*

**ANTIBODY–DRUG CONJUGATES**  
**Moderatori:** Marina Elena Cazzaniga, Saverio Cinieri, Alberto Zambelli

11.10  **Current role of Antibody–drug conjugates in the treatment of metastatic breast cancer**  
Alessandra Gennari

11.25  **New Antibody–drug conjugates at the horizon**  
Michelino De Laurentis

11.40  **Resistance to Antibody–drug conjugates: mechanisms and biomarkers**  
Carmine De Angelis

11.55  **Managing Antibody–drug conjugates specific toxicity**  
Erica Moretti

12.20  **Discussion**

12.40  *Light lunch*

**IMMUNOTHERAPY**  
**Moderatori:** Catia Angiolini, Carmelo Bengala, Claudio Zamagni

14.00  **Precision immunology in breast cancer**  
Maria Vittoria Dieci

14.15  **Optimizing first-line therapy in triple negative breast cancer**  
Fabio Puglisi

14.30  **New immunotherapies and combinations in breast cancer**  
Giampaolo Bianchini

14.45  **Discussion**

15.15  **Take home messages**  
Laura Biganzoli, Luca Malorni

15.30  **Adjourn**
COURSE DIRECTORS

Laura Biganzoli
S.O.C. Oncologia Medica
Nuovo Ospedale di Prato Santo Stefano
Azienda USL Toscana Centro
Prato

Luca Malorni
S.O.S. Ricerca Traslazionale
S.O.C. Oncologia Medica
Nuovo Ospedale di Prato Santo Stefano
Azienda USL Toscana Centro
Prato

SCIENTIFIC SECRETARIAT

Matteo Benelli
Unità di Bioinformatica
S.O.C. Oncologia Medica
Nuovo Ospedale di Prato Santo Stefano
Azienda USL Toscana Centro
Prato

Ilenia Migliaccio
S.O.S. Ricerca Traslazionale
S.O.C. Oncologia Medica
Nuovo Ospedale di Prato Santo Stefano
Azienda USL Toscana Centro
Prato

Erica Moretti
S.O.C. Oncologia Medica
Nuovo Ospedale di Prato Santo Stefano
Azienda USL Toscana Centro
Prato
Faculty

Catia Angiolini, Firenze
Grazia Arpino, Napoli
Matteo Benelli, Prato
Carmelo Bengala, Pisa
Rossana Berardi, Ancona
Silvia Bessi, Prato
Giampaolo Bianchini, Milano
Marina Elena Cazzaniga, Monza
Saverio Cinieri, Brindisi
Carmen Criscitiello, Milano
Pierfranco Conte, Padova
Giuseppe Curigliano, Milano
Carmine De Angelis, Napoli
Michelino De Laurentiis, Napoli
Sabino De Placido, Napoli
Lucia Del Mastro, Genova
Maria Vittoria Dieci, Padova
Alessandra Fabi, Roma
Luisa Fioretto, Firenze
Daniele Generali, Trieste
Alessandra Gennari, Novara
Mario Giuliano, Napoli
Cristina Guarducci, Prato
Valentina Guarneri, Padova
Luca Livraghi, Prato
Luca Malorni, Prato
Cristina Manetti, Firenze
Francesca Martella, Firenze
Maria Teresa Mechi, Prato
Ilenia Migliaccio, Prato
Erica Moretti, Prato
Francesco Perrone, Napoli
Martine Piccart, Brussels
Giancarlo Pruner, Milano
Fabio Puglisi, Udine - Aviano (PN)
Miriam Ricasoli, Pistoia
Emanuela Risi, Prato
Angela Toss, Modena
Claudio Zamagni, Bologna
Alberto Zambelli, Milano
Gabriele Zoppoli, Genova
Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the CME activity (31-409133): 9 CME credits.

Training objective: professional and technical content (knowledge and skills) each profession, specialization and highly specialized activity. Rare disease.

The credit certification for the activity is subject to:
• professions/specializations should correspond to those which have been;
• attendance at the 90% of the meeting;
• the completion of the Meeting evaluation online form;
• completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Participation in the course is free, places available are limited.

It is possible to register online at https://fad.accmed.org/course/info.php?id=1522 by April 20. Registration will be accepted in the chronological order of arrival and will be confirmed by e-mail.

Per ragioni organizzative si segnala che il meeting verrà svolto in lingua inglese il 18 aprile e in lingua italiana il 19 aprile.
VENUE

Camera di Commercio di Pistoia-Prato - Sede di Prato
Via del Romito, 71
59100 Prato PO

ORGANIZER

ACCADEMIA NAZIONALE DI MEDICINA
Direttore Generale: Stefania Ledda
Via Martin Piaggio 17/6
16122 Genova

INFORMATION

fad.accmed.org
Ph: 010 83794239
Mob: 3357112604
segreteriacorsi@accmed.org

LOGISTICS AND TECHNOLOGICAL SERVICES

Forum Service
Via Martin Piaggio 17/7
16122 Genova

Supported by unrestricted educational grants from

Gold

AstraZeneca

MSD

Silver

Daiichi-Sankyo

AstraZeneca

Lilly

Bronze

GILEAD

Menarini

Stemline

Takeda

Contributors

EXACT SCIENCES

NOVARTIS

Pfizer

Roche